Anacor Pharmaceuticals Inc  

(Public, NASDAQ:ANAC)   Watch this stock  
Find more results for ANAC
79.86
+0.10 (0.13%)
Jul 7 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 77.22 - 80.99
52 week 14.95 - 81.76
Open 79.98
Vol / Avg. 419,871.00/644,252.00
Mkt cap 3.49B
P/E     -
Div/yield     -
EPS -1.86
Shares 43.75M
Beta 1.35
Inst. own 95%
Aug 5, 2015
Q2 2015 Anacor Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 10, 2015
Anacor Pharmaceuticals Inc at Goldman Sachs Healthcare Conference
Jun 9, 2015
Anacor Pharmaceuticals Inc Annual Shareholders Meeting
Jun 2, 2015
Anacor Pharmaceuticals Inc at Jefferies Global Healthcare Conference
May 13, 2015
Anacor Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference
May 7, 2015
Anacor Pharmaceuticals Inc at Deutsche Bank Health Care Conference
May 6, 2015
Q1 2015 Anacor Pharmaceuticals Inc Earnings Call - Webcast
May 6, 2015
Q1 2015 Anacor Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -84.91% -421.28%
Operating margin -77.28% -449.66%
EBITD margin - -436.51%
Return on average assets -24.53% -45.72%
Return on average equity -68.66% -87.03%
Employees 100 -
CDP Score - -

Address

1020 East Meadow Circle
PALO ALTO, CA 94303-4230
United States - Map
+1-650-5437500 (Phone)
+1-650-5437660 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Anacor Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform. The Company's lead product candidate, AN2728 is an investigational non-steroidal topical PDE-4 inhibitor in development for the potential treatment of mild-to-moderate atopic dermatitis and psoriasis. The Company's product KERYDIN (tavaborole) topical solution is an oxaborole antifungal. The Company also has a pipeline of other internally discovered topical and systemic boron-based compounds in early stages of research and development, which include AN3365. The Company's compound, AN5568 (SCYX-7158), is licensed to Drugs for Neglected Diseases initiative (DNDi) for the potential treatment of human African trypanosomiasis (sleeping sickness).

Officers and directors

Paul L. Berns Chairman of the Board, President, Chief Executive Officer
Age: 48
Bio & Compensation  - Reuters
Graeme Bell Chief Financial Officer, Executive Vice President
Bio & Compensation  - Reuters
Vincent P. Ippolito Executive Vice President, Chief Commercial Officer
Age: 56
Bio & Compensation  - Reuters
Ryan T. Sullivan Senior Vice President, General Counsel, Secretary
Age: 39
Bio & Compensation  - Reuters
Sanjay Chanda Ph.D. Senior Vice President - Drug Development
Age: 50
Bio & Compensation  - Reuters
Kirk R. Maples Ph.D. Senior Vice President - Program Management
Age: 56
Bio & Compensation  - Reuters
Jacob J. Plattner Ph.D. Senior Vice President - Research
Age: 68
Bio & Compensation  - Reuters
Carmen R. Rodriguez Ph.D. Senior Vice President - Regulatory Affairs and Quality Assurance
Age: 66
Bio & Compensation  - Reuters
Lee T. Zane M.D. Senior Vice President - Clinical Development, Chief Medical Officer
Age: 45
Bio & Compensation  - Reuters
William J. Rieflin Lead Independent Director
Age: 55
Bio & Compensation  - Reuters